Please assess the completion status of the following clinical trial:

Trial Title: Alemtuzumab/Fludarabine for Relapsed/Refractory B-cell Chronic Lymphocytic Leukemia (B-CLL)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patient must have confirmed B-CLL.~* Patients must have received at least one prior therapy and must require treatment for active disease~Exclusion Criteria:~* Treatment with any anti-cancer agents (chemotherapies, monoclonal antibodies, etc) within 4 weeks of start of study.~* History of significant allergic reaction to antibody therapies that required discontinuation of antibody therapy~* History of human immunodeficiency virus (HIV) positivity.~* Active infection requiring treatment~* Pregnancy or lactation~* Other severe, concurrent diseases or mental disorders~* Central nervous system involvement of chronic lymphocytic leukemia (CLL)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Alemtuzumab plus Fludarabine (Type: EXPERIMENTAL): Alemtuzumab (Campath) 30mg subcutaneous (SC) plus Fludarabine (Fludara) 25mg/m² intravenous (IV), Days 1-5 every 28 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).